GlassScriptPhysician profile
Jane R Conley
NPI 1407801608
$3,314.75
in general payments reported to CMS, 2019-2025
20 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $69.81 · 2021: $117 · 2022: $490 · 2023: $582 · 2024: $774 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.60 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $583.68 | 2023-2025 | Xolair |
| Glaxosmithkline, LLC. | $560.72 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $460.98 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $315.16 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $303.53 | 2019-2025 | Fasenra, Tezspire |
| Sanofi-Aventis U.S. LLC | $192.98 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $151.07 | 2019-2025 | |
| Kaleo, INC. | $128.37 | 2020-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $100.52 | 2021-2022 | |
| Optinose US, INC. | $90.42 | 2024-2025 | |
| Grifols USA, LLC | $88.53 | 2024-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $71.83 | 2020-2022 | |
| Csl Behring | $47.55 | 2025 | Andembry, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $47.20 | 2025 | Neffy |
| Octapharma USA, INC. | $43.86 | 2023-2024 | Cutaquig |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.37 | 2019 | |
| Cycle Pharmaceuticals INC | $38.86 | 2025 | Sajazir |
| Pfizer INC. | $18.27 | 2025 | |
| Amgen INC. | $14.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.